These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11453304)

  • 1. Mode of action and tissue dosimetry in current and future risk assessments.
    Andersen ME; Dennison JE
    Sci Total Environ; 2001 Jul; 274(1-3):3-14. PubMed ID: 11453304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologically based modeling in toxicology research.
    Andersen ME; Krishnan K; Conolly RB; McClellan RO
    Arch Toxicol Suppl; 1992; 15():217-27. PubMed ID: 1510591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic-induced carcinogenesis--oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment.
    Kitchin KT; Conolly R
    Chem Res Toxicol; 2010 Feb; 23(2):327-35. PubMed ID: 20035570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of mechanistic data in risk assessment: the past, present, and future.
    Haber LT; Maier A; Zhao Q; Dollarhide JS; Savage RE; Dourson ML
    Toxicol Sci; 2001 May; 61(1):32-9. PubMed ID: 11294971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical factors in assessing risk from exposure to nasal carcinogens.
    Bogdanffy MS; Mathison BH; Kuykendall JR; Harman AE
    Mutat Res; 1997 Oct; 380(1-2):125-41. PubMed ID: 9385394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-response assessment strategies for endocrine-active compounds.
    Barton HA; Andersen ME
    Regul Toxicol Pharmacol; 1997 Jun; 25(3):292-305. PubMed ID: 9237331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologically based pharmacodynamic models: tools for toxicological research and risk assessment.
    Conolly RB; Andersen ME
    Annu Rev Pharmacol Toxicol; 1991; 31():503-23. PubMed ID: 2064384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
    Clewell HJ; Gentry PR; Gearhart JM
    J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicokinetic modeling and its applications in chemical risk assessment.
    Andersen ME
    Toxicol Lett; 2003 Feb; 138(1-2):9-27. PubMed ID: 12559690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research needs and advances in inhalation dosimetry identified through the use of mathematical dosimetry models of ozone.
    Miller FJ; Graham JA
    Toxicol Lett; 1988 Dec; 44(3):231-46. PubMed ID: 3217941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors.
    Andersen ME; Clewell H; Krishnan K
    Risk Anal; 1995 Aug; 15(4):533-7. PubMed ID: 7480953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk assessment and biological mechanisms: lessons learned, future opportunities.
    McClellan RO
    Toxicology; 1995 Sep; 102(1-2):239-58. PubMed ID: 7482559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What role for biologically based dose-response models in estimating low-dose risk?
    Crump KS; Chen C; Chiu WA; Louis TA; Portier CJ; Subramaniam RP; White PD
    Environ Health Perspect; 2010 May; 118(5):585-8. PubMed ID: 20056564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of mode of action information in risk assessment: quantitative key events/dose-response framework for modeling the dose-response for key events.
    Simon TW; Simons SS; Preston RJ; Boobis AR; Cohen SM; Doerrer NG; Fenner-Crisp PA; McMullin TS; McQueen CA; Rowlands JC;
    Crit Rev Toxicol; 2014 Aug; 44 Suppl 3():17-43. PubMed ID: 25070415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicology and carcinogenesis studies of a mixture of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Cas No. 1746-01-6), 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) (Cas No. 57117-31-4), and 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (Cas No. 57465-28-8) in female Harlan Sprague-Dawley rats (gavage studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 Sep; (526):1-180. PubMed ID: 17342195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
    Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
    Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NTP technical report on the toxicology and carcinogenesis studies of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (CAS No. 1746-01-6) in female Harlan Sprague-Dawley rats (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 Apr; (521):4-232. PubMed ID: 16835633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue dosimetry, physiologically-based pharmacokinetic modeling, and cancer risk assessment.
    Andersen ME
    Cell Biol Toxicol; 1989 Dec; 5(4):405-15. PubMed ID: 2627676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologically motivated computational modeling of formaldehyde carcinogenicity in the F344 rat.
    Conolly RB; Kimbell JS; Janszen D; Schlosser PM; Kalisak D; Preston J; Miller FJ
    Toxicol Sci; 2003 Oct; 75(2):432-47. PubMed ID: 12857938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chloroform mode of action: implications for cancer risk assessment.
    Golden RJ; Holm SE; Robinson DE; Julkunen PH; Reese EA
    Regul Toxicol Pharmacol; 1997 Oct; 26(2):142-55. PubMed ID: 9356278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.